TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T22118	Dopamine D1 receptor	D0I8FI	Isoproterenol	Approved	3779	C11H17NO3	211.26	CC(C)NCC(C1=CC(=C(C=C1)O)O)O	Ki ~ 50000 nM	Poor binder
T22118	Dopamine D1 receptor	B1NMB8	2-[[(2R)-2-Phenethylmorpholino]methyl]-1H-benzoimidazole	Investigative	60149678	C20H23N3O	321.4	C1CO[C@@H](CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	B7OMK0	4-(1H-Benzimidazol-2-ylmethyl)-2-(2-phenylethyl)morpholine	Investigative	19964406	C20H23N3O	321.4	C1COC(CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BB1OJ3	[(1R,2S,5S,6S,7S)-3-Benzyl-7-(diethylamino)-2-pyridin-2-yl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70688594	C23H31N3O	365.5	CCN(CC)[C@@H]1[C@H]([C@@H]2[C@H]1[C@H](N(C2)CC3=CC=CC=C3)C4=CC=CC=N4)CO	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BC2SZ6	(2S)-4-(1H-Benzimidazol-2-ylmethyl)-2-(2-phenylethyl)morpholine	Investigative	92640710	C20H23N3O	321.4	C1CO[C@H](CN1CC2=NC3=CC=CC=C3N2)CCC4=CC=CC=C4	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BCFK50	4-Methyl-5-[4-methyl-5-[3-[(2S,3R)-2-phenyl-5-azaspiro[2.4]heptan-5-yl]propylsulfanyl]-1,2,4-triazol-3-yl]-1,3-oxazole	Investigative	121304458	C22H27N5OS	409.5	CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC[C@]4(C3)C[C@H]4C5=CC=CC=C5	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BFG51U	[(1S,2R,5S,6S,7S)-3-Benzyl-2-methyl-7-pyrrolidin-1-yl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70686494	C19H28N2O	300.4	C[C@@H]1[C@@H]2[C@H](CN1CC3=CC=CC=C3)[C@@H]([C@H]2N4CCCC4)CO	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BIY6T3	[(1S,2R,5S,6S,7S)-3-Benzyl-7-(diethylamino)-2-methyl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70684338	C19H30N2O	302.5	CCN(CC)[C@@H]1[C@H]([C@@H]2[C@H]1[C@H](N(C2)CC3=CC=CC=C3)C)CO	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BOI29T	CN1C(Scccn2ccoc(C2)C2=CC=C(C=C2)C(F)(F)F)=NN=C1C1=C(C)N=CO1	Investigative	127041952	C21H24F3N5O2S	467.5	CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCOC(C3)C4=CC=C(C=C4)C(F)(F)F	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BW1E3H	(+)-Govadine HCl	Investigative	57401392	C19H22ClNO4	363.8	COC1=C(C=C2[C@H]3CC4=CC(=C(C=C4CN3CCC2=C1)O)OC)O.Cl	EC50 ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BWC03E	[(1R,2S,5R,6R,7R)-3-Benzyl-2-methyl-7-pyrrolidin-1-yl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70684339	C19H28N2O	300.4	C[C@H]1[C@H]2[C@@H](CN1CC3=CC=CC=C3)[C@H]([C@@H]2N4CCCC4)CO	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BXUG13	[(1S,2R,5R,6R,7R)-3-Benzyl-7-(diethylamino)-2-pyridin-2-yl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70692802	C23H31N3O	365.5	CCN(CC)[C@H]1[C@@H]([C@H]2[C@@H]1[C@@H](N(C2)CC3=CC=CC=C3)C4=CC=CC=N4)CO	Ki ~ 100000 nM	Poor binder
T22118	Dopamine D1 receptor	BZ60AW	[(1R,2S,5R,6R,7R)-3-Benzyl-7-(diethylamino)-2-methyl-3-azabicyclo[3.2.0]heptan-6-yl]methanol	Investigative	70686493	C19H30N2O	302.5	CCN(CC)[C@H]1[C@@H]([C@H]2[C@@H]1[C@@H](N(C2)CC3=CC=CC=C3)C)CO	Ki ~ 100000 nM	Poor binder